Drugs / OXN PR
last change Sep 2015 re-read 2 minutes ago

OXN PR

Developed for
chronic pain syndrome
Investigated by
Mundipharma Research GmbH & Co KG

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01915147 Jul 2013 → Feb 2015 chronic pain syndrome Mundipharma Research GmbH & Co KG Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as OXN PR ClinicalTrials.gov intervention name — accepted as the source's own label NCT01915147